Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $5,447,141.70 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 23,205 shares of Natera stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the sale, the insider owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $68,855.00.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.

Natera Trading Down 0.5%

NASDAQ:NTRA opened at $241.58 on Friday. The company has a market capitalization of $33.42 billion, a P/E ratio of -105.49 and a beta of 1.62. The firm has a 50-day moving average price of $234.18 and a two-hundred day moving average price of $191.40. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue was up 34.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.26) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on NTRA. Guggenheim lifted their price target on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. JPMorgan Chase & Co. upped their price target on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. BTIG Research lifted their price target on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $245.50.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Institutional Investors Weigh In On Natera

Large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in Natera by 168.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,373 shares of the medical research company’s stock worth $544,000 after purchasing an additional 1,489 shares during the period. Octavia Wealth Advisors LLC acquired a new position in shares of Natera during the fourth quarter worth about $1,042,000. Assetmark Inc. boosted its position in shares of Natera by 4.4% in the fourth quarter. Assetmark Inc. now owns 17,401 shares of the medical research company’s stock worth $3,986,000 after buying an additional 737 shares during the period. Transcend Capital Advisors LLC grew its stake in shares of Natera by 27.2% in the fourth quarter. Transcend Capital Advisors LLC now owns 2,381 shares of the medical research company’s stock valued at $545,000 after buying an additional 509 shares in the last quarter. Finally, Choreo LLC raised its holdings in shares of Natera by 18.8% during the 4th quarter. Choreo LLC now owns 2,211 shares of the medical research company’s stock valued at $508,000 after buying an additional 350 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.